Phase II Efficacy and Safety Study of Dasatinib in Patients With Chronic and Accelerated Phase Chronic Myeloid Leukemia Relapsing After Allogeneic Blood or Bone Marrow Transplantation.
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2015
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 May 2011 Planned end date changed from 1 Jun 2014 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 03 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.